ASCO twenty twenty-six opens today, and AI just lifted lung-cancer biomarker testing by twenty-four percent.

Run time: 19:27

In today's episode:

1. Tempus Next lifts lung-cancer biomarker testing by twenty-four percent
2. Mayo Clinic brings thirty oncology AI studies to ASCO
3. Sylvester AI reads bone marrow to personalize myeloma therapy
4. Penn Medicine flags AI gaps in patient cancer info
5. NEJM AI publishes MEDS open data standard for health AI
6. Anthropic ships Claude Opus four point eight with dynamic workflows
7. Anthropic in talks to raise sixty-five billion at nine-hundred-sixty-five billion
8. Mythos moves toward broader release after ten thousand bugs found

TL;DR:

• ASCO 2026 kicks off in Chicago today — Tempus Next's AI clinical decision support lifted real-world biomarker-testing rates by +24% ALK, +18% EGFR, +13% PD-L1 in early-stage NSCLC across six community health systems, a rare deployed-AI outcomes win.
• Anthropic released Claude Opus 4.8 yesterday — high-effort default, dynamic workflows spawning hundreds of parallel subagents, agentic coding jumps 64.3→69.2%, ~4× fewer flawed-code passes, fast mode 3× cheaper. Pricing held at $5/$25 per M tokens.
• NEJM AI published the MEDS (Medical Event Data Standard) review on May 28 — an open data framework now used at 21 institutions and 27 papers that aims to fix reproducibility/portability in EHR-based clinical AI.

Sources cited:

• businesswire
• Mayo News Network
• Newswise
• Penn Medicine
• NEJM AI
• Harvard Science Review
• Anthropic
• TechCrunch
• US News
• MEDS overview

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.